Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards to Kristin Yarema, its Chief Commercial Officer.
The compensation committee of Atara’s board of directors granted Ms. Yarema a stock option to purchase 110,000 shares of Atara’s common stock effective as of February 18, 2020, and restricted stock units to acquire 55,000 shares of Atara’s common stock effective as of March 1, 2020. The stock option and restricted stock units were granted as an inducement material to Ms. Yarema entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has a ten-year term and an exercise price of $14.56, equal to the per share closing price of Atara's common stock as reported by Nasdaq on February 18, 2020. The awards vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting over the following three years, assuming Ms. Yarema is continuously employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by its manufacturing facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.
INVESTOR & MEDIA CONTACTS:
Kerry Beth Daly
Head, Corporate Communications
John Craighead, Ph.D.
Vice President, Investor Relations & Corporate Communications
Released February 21, 2020